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Abstract
Background—In 2010, Mexico was the most common (22.9%) country of origin for foreign-
born persons with tuberculosis in the United States, and overall trends in tuberculosis morbidity 
are substantially influenced by the Mexico-born population.
Objectives—To determine the risk of tuberculosis disease among Mexico-born persons living in 
the United States.
Methods—Using data from the U.S. National Tuberculosis Surveillance System and the 
American Community Survey, we examined tuberculosis case counts and case rates stratified by 
years since entry into the United States and geographic proximity to the United States–Mexico 
border. We calculated trends in case rates over time measured by average annual percent change.
Results—The total tuberculosis case count (−14.5%) and annual tuberculosis case rate (average 
annual percent change −5.1%) declined among Mexico-born persons. Among those diagnosed 
with tuberculosis less than 1 year since entry into the United States (newly arrived persons), there 
was a decrease in tuberculosis cases (−60.4%), no change in tuberculosis case rate (average annual 
percent change of 0.0%), and a decrease in population (−60.7%). Among those living in the 
United States for more than 5 years (non-recently arrived persons), there was an increase in 
tuberculosis cases (+3.4%), a decrease in tuberculosis case rate (average annual percent change of 
−4.9%), and an increase in population (+62.7%). In 2010, 66.7% of Mexico-born cases were 
among non–recently arrived persons, compared with 51.1% in 2000. Although border states 
reported the highest proportions (>15%) of tuberculosis cases that were Mexico-born, the highest 
Mexico-born–specific tuberculosis case rates (>20/100,000 population) were in states in the 
eastern and southeastern regions of the United States.
Conclusions—The decline in tuberculosis morbidity among Mexico-born persons may be 
attributed to fewer newly arrived persons from Mexico and lower tuberculosis case rates among 
non–recently arrived Mexico-born persons. The extent of the decline was dampened by an 
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unchanged tuberculosis case rate among newly arrived persons from Mexico and a large increase 
in the non–recently arrived Mexico-born population. If current trends continue, tuberculosis 
morbidity among Mexico-born persons will be increasingly driven by those who have been living 
in the United States for more than 5 years.
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Every year since 2004, over 50% of reported tuberculosis cases in the United States 
occurred among foreign-born persons (1). Mexico was the most common (22.9%) reported 
country of origin for foreign-born persons with tuberculosis in 2010 (2). An estimated 12 
million Mexico-born persons lived in the United States in 2010, composing 28.2% of the 
foreign-born population (3).
Previous studies have characterized the challenges of tuberculosis prevention and care 
among Mexico-born persons, including repatriation before treatment completion (4) and 
barriers to accessing care associated with immigration status (5, 6). During 1993–2001, 
tuberculosis among Mexico-born persons in the United States occurred primarily in states 
along the United States–Mexico border, and approximately one-quarter of tuberculosis cases 
in border states occurred among Mexico-born persons (7). As a result, U.S. tuberculosis 
control policy surrounding Mexico-born persons has focused on interventions along the 
border between the United States and Mexico (8).
Beginning in 2007, the United States implemented enhanced preimmigration screening for 
tuberculosis disease among applicants for immigration from Mexico (and other countries) 
before arrival in the United States (9). In addition, U.S. tuberculosis control efforts extend 
beyond screening of immigrant applicants for disease; preventing tuberculosis in foreign-
born persons with latent tuberculosis infection (through targeted testing and treatment) has 
become a high priority (10), given that three-quarters of all tuberculosis cases in foreign-
born persons are thought to be from reactivation of latent tuberculosis infection (11). The 
potential impact of different targeted testing strategies among foreign-born persons has been 
debated extensively (10, 12–19), but an evidence-based approach specific to Mexico-born 
persons has not been previously studied. Some data included in this article have been 
presented previously in abstract form (20).
Methods
Study Population
Using data from the U.S. National Tuberculosis Surveillance System (2) and the U.S. 
National Tuberculosis Genotyping Service (21), we examined all verified cases of 
tuberculosis reported during 2000–2010. Cases were classified into three groups based on 
the reported country of birth: Mexico-born, United States-born (U.S.-born), and foreign-
born from countries other than Mexico (foreign-born other). Cases missing data on country 
of birth or born as U.S. citizens outside of the United States were excluded from the 
analysis.
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Population estimates were derived from 1-year estimates from the American Community 
Survey, an ongoing statistical survey that samples approximately 1.9 million households 
over the course of each year (22). Persons are included in this survey regardless of 
immigration status. Population estimates are subdivided into public use microdata areas, 
which each contain a population of approximately 100,000 individuals. Tuberculosis case 
rates were calculated as the number of cases per 100,000 persons for each subpopulation. 
For example, the tuberculosis case rate among Mexico-born persons for each year was 
calculated using the number of tuberculosis cases among Mexico-born persons reported 
during that year and the estimated population of Mexico-born persons living in the United 
States during that same year. The 5- and 10-year case rates were calculated using aggregate 
case counts and aggregate population estimates for each time period.
We compared select demographic and clinical characteristics between U.S.-born, Mexico-
born, and foreign-born other tuberculosis cases. The chi-square test was used to detect 
differences in proportions of individuals. We also examined tuberculosis case rates stratified 
by geographic proximity to the United States–Mexico border. Border states were defined as 
those that border with Mexico (i.e., California, Texas, New Mexico, and Arizona). Border 
areas were defined as public use microdata areas directly bordering Mexico and have been 
described elsewhere (23).
Joinpoint Regressional Software, version 3.5.2 (National Cancer Institute, Bethesda, MD), 
was used to calculate the average annual percent change of population estimates and 
tuberculosis case rates over the period of study (24). Standard errors for the population 
estimates and case rates were calculated using design factors (2000–2004) or replicate 
weights (2005–2010) per recommendations of the U.S. Census Bureau (22). In Joinpoint, P 
values for regression lines are calculated using a t test; if the P value was less than 0.05, then 
the slope was considered to be significantly different than zero.
The methods used to calculate tuberculosis case rates stratified by years since entry into the 
United States are described elsewhere (13). We stratified Mexico-born persons into three 
groups based upon years since U.S. entry: newly arrived (tuberculosis diagnosis <1 yr since 
U.S. entry), recently arrived (1–5 yr since U.S. entry), and non–recently arrived (>5 yr since 
U.S. entry). Mycobacterium bovis was identified using genotyping results of routinely 
collected isolates from reported tuberculosis cases (21, 25).
Aside from average annual percent change calculations, analyses were conducted using 
SAS, version 9.3 (SAS Institute, Cary, NC), and, for all statistical tests, results were 
considered to be significant if P was less than 0.05.
Ethical Review
Data for the U.S. National Tuberculosis Surveillance System and National Tuberculosis 
Genotyping Service are collected as part of routine public health practice, and therefore this 
project was determined not to be human subject research requiring institutional review board 
approval.
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Tuberculosis Case Counts and Case Rates
During 2000–2010, there were 153,353 cases of tuberculosis reported in the United States; 
539 cases with no reported information on birth country or born as U.S. citizens outside the 
United States were excluded from further analysis. The remaining 152,814 cases included 
69,189 (45.3%) among U.S.-born persons, 20,254 (13.3%) among Mexico-born persons, and 
63,371 (41.5%) among foreign-born other persons.
The number of tuberculosis cases among Mexico-born persons declined 14.5%, from 1,802 
cases in 2000 to 1,541 cases in 2010, whereas tuberculosis among foreign-born other 
persons declined 11.0%. The overall tuberculosis case rate for the 10-year period was higher 
among the foreign-born other population (21.5/100,000 population) compared with the 
Mexico-born population (17.0/100,000 population). Annual tuberculosis case rates declined 
among both groups, with an average annual percent change of −4.2% among foreign-born 
other and −5.1% among Mexico-born persons (Figure 1).
Clinical and Demographic Characteristics
During 2000–2010, Mexico-born persons with tuberculosis were more frequently sputum 
smear–positive (54.1%) than foreign-born other (42.9%) and U.S.-born (45.0%) persons, 
and more frequently presented with cavitary disease (32.8 vs. 24.3 vs. 29.4%, respectively) 
(Table 1). Mexico-born persons had the lowest treatment completion rate (87.1 vs. 91.6 vs. 
93.6%), and represented the highest proportion of persons with tuberculosis who moved or 
were lost to follow up (9.9 vs. 5.9 vs. 3.3%).
Among Mexico-born persons, 5.2% had isoniazid-monoresistant tuberculosis (resistant to 
isoniazid, but susceptible to rifampin) and 1.1% had multidrug-resistant tuberculosis 
(resistant to at least isoniazid and rifampin), lower than foreign-born other persons (7.4 and 
1.4%), but greater than U.S.-born persons (3.1 and 0.4%). However, 4.1% of Mexico-born 
persons had pyrazinamide-monoresistant tuberculosis, compared with 0.7% among foreign-
born other persons and 0.8% among U.S.-born persons. Among all cases with pyrazinamide-
monoresistance and known genotyping results (2005–2010), 56.7% of isolates were M. 
bovis (89.5% among Mexico-born, 12.2% among foreign-born other, and 51.8% among 
U.S.-born persons).
Among Mexico-born persons with tuberculosis, 6.6% were incarcerated at diagnosis, a 
proportion higher than foreign-born other (1.5%) and U.S.-born (4.7%) persons. In 2010 
only, 121 (9.7%) Mexico-born persons with tuberculosis were incarcerated at the time of 
diagnosis, (the highest percentage among any group during the period of study), with 33.1% 
diagnosed in jail, 24.1% in a state or federal prison, and 42.8% in “other” locations, 
including U.S. Immigration and Customs Enforcement facilities. Among Mexico-born 
persons who were incarcerated at tuberculosis diagnosis, approximately half (49.9%) 
completed treatment, lower than completion rates among foreign-born other (63.7%) and 
U.S.-born (83.5%) persons incarcerated at diagnosis.
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Proximity to the United States–Mexico Border
Western and southwestern states reported the highest proportions (>15%) of tuberculosis 
cases that were Mexico-born (Figure 2A). However, the highest Mexico-born–specific 
tuberculosis case rates (>20/100,000 population) were reported in states in the eastern and 
southeastern regions of the United States (Figure 2B).
Meanwhile, in border areas, all adult groups had higher tuberculosis case rates when 
compared with nonborder states (Table 2), with the greatest relative case rate increase 
among U.S.-born Hispanic adults (+95.9%), followed by foreign-born other (+77.7%), 
Mexico-born (+68.0%), and U.S.-born non-Hispanic adults (+17.7%). Both U.S.-born 
Hispanic and Mexico-born children in border areas had higher case rates (+72.9 and 
+60.9%, respectively) when compared with those populations in nonborder states.
Years since Entry into the United States
Overall, newly arrived (<1 yr) foreign-born other persons had higher tuberculosis case rates 
when compared with newly arrived Mexico-born persons (112.4/100,000 population vs. 
72.5/100,000 population; Figure 3). Although both groups experienced declines in case rate 
from 1 to 10 years after U.S. entry from 10 to 25 years there was a decreasing tuberculosis 
case rate among the foreign-born other population (from 19.5/100,000 population to 
12.6/100,000 population), whereas the tuberculosis case rate among the Mexico-born 
population remained relatively constant (12.3/100,000 population to 12.5/100,000 
population).
The difference between the two groups gradually diminished as years since U.S. entry 
increased. The tuberculosis case rate among the foreign-born other population further 
declined after 25 years, and reached a nadir of 5.8/100,000 population at 50 years since U.S. 
entry. The tuberculosis case rate among Mexico-born persons gradually increased from 25 to 
50 years since U.S. entry, and reached 24.0/100,000 population after 50 years in the United 
States—4.1 times the case rate among foreign-born other persons for the same time since 
U.S. entry.
Trends in Tuberculosis Case Counts and Case Rates Stratified by Years since Entry into 
the United States
Comparing 2000 to 2010, the number of cases diagnosed among newly arrived (<1 yr) 
Mexico-born persons decreased by 60.4% (from 391 to 155 cases), and cases among 
recently arrived (1–5 yr) declined by 33.6% (from 452 to 300 cases). At the same time, the 
number of non-recently arrived (>5 yr) Mexico-born cases increased slightly, by 3.4% (from 
880 to 910 cases).
Examining population trends alone, the estimate of non-recently arrived (>5 yr) Mexico-
born persons increased 62.7%, from 6.2 million in 2000 to 10.0 million in 2010 (average 
annual percent change, +4.4%; P < 0.05). At the same time, the estimated population of 
recently arrived (1–5 yr) Mexico-born persons decreased 25.7%, from 2.3 million to 1.7 
million (average annual percent change, −4.4%; P < 0.05), and the estimated population of 
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newly arrived (<1 yr) Mexico-born persons decreased 60.7%, from 0.6 million to 0.2 million 
(average annual percent change, −9.3%; P < 0.05).
During the study period, the annual tuberculosis case rate among Mexico-born persons 
remained relatively constant among newly arrived persons (average annual percent change, 
0.0%; P = 0.99), declined slightly among recently arrived persons (average annual percent 
change, −2.0%; P = 0.04), and experienced a significant decline among non-recently arrived 
(>5 yr) persons (average annual percent change, −4.9%; P < 0.01) (Figure 4).
Discussion
Several demographic and clinical characteristics distinguish Mexico-born persons with 
tuberculosis from those born in the United States and countries other than Mexico. High 
proportions of sputum smear–positive (54.1%) and cavitary disease (32.8%) among Mexico-
born persons suggest greater severity of disease, potentially due to delayed diagnosis and 
initiation of treatment (26). Several factors may contribute to this phenomenon; a large 
number of Mexico-born persons living in the United States are undocumented (6.6 million 
in 2010) (27), and undocumented persons with tuberculosis may have poor access to care (5, 
6, 28). In addition, compared with foreign-born persons from countries other than Mexico, 
Mexico-born persons tend to be less educated and less likely to be fluent in English (29), 
making medical services particularly difficult for this population to reach.
Among Mexico-born persons, we found high rates of incarceration at the time of diagnosis 
(9.7% in 2010) and low rates of reported treatment completion among those incarcerated 
(49.9%). The incarceration facility type for a large proportion (42.8%) of Mexico-born 
persons was categorized as “other,” including Immigration and Customs Enforcement 
facilities. The U.S. National Tuberculosis Surveillance System recently began recording 
information specifically regarding persons diagnosed in Immigration and Customs 
Enforcement custody; future analyses may help identify any potential association between 
incarceration facility type and rates of treatment completion.
High rates of incarceration, combined with low rates of treatment completion among 
incarcerated Mexico-born persons (49.9%), are concerning, as persons who fail to complete 
treatment are more likely to have recurrent disease (30). An unknown proportion of Mexico-
born persons diagnosed with tuberculosis at the time of incarceration move back to Mexico 
(either by choice after release from custody, or by repatriation), and, therefore, definitive 
data on completion rates are unavailable at this time.
Although the largest proportion of Mexico-born tuberculosis cases are diagnosed in border 
states (Figure 2A), the highest Mexico-born–specific tuberculosis case rates are not found in 
border states, but rather states in the eastern and southeastern regions of the United States 
(Figure 2B). Given these findings, future tuberculosis prevention, diagnosis, and care 
activities aimed at Mexico-born persons should not focus on border states to the exclusion of 
nonborder states. Possible activities focused on these areas with high Mexico-born-specific 
tuberculosis case rates could include improving access to medical care for Mexico-born 
persons, providing culturally sensitive education regarding the signs and symptoms of 
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tuberculosis disease to immigrant communities, encouraging local providers serving these 
communities to consider tuberculosis disease in Mexico-born persons with appropriate 
clinical presentations, and increasing routine targeted testing and treatment for latent 
tuberculosis infection.
Despite the lower tuberculosis case rates in border states compared with some nonborder 
states, tuberculosis cases rates were highest in border areas, with the largest relative case 
rate increase among the U.S.-born Hispanic population (Table 2). A recent analysis 
suggested that tuberculosis transmission commonly occurs among U.S.-born and Mexico-
born persons, particularly along the United States–Mexico border (23). This phenomenon 
requires further study to explore the potential relationship between U.S.-born and Mexico-
born cases along the border, such as transmission within families with Mexico-born adults 
and U.S.-born Hispanic children.
When examining tuberculosis case rates by years since U.S. entry we found that the case 
rate among newly (<1 yr) or recently arrived (1–5 yr) Mexico-born persons is more than 
twice that of nonrecent arrivers (>5 yr) (29.2/100,000 population vs. 12.0/100,000 
population) (Figure 3). However, we also found that the tuberculosis case rate among 
Mexico-born persons who have been in the United States for more than 10 years remained 
elevated decades after U.S. entry, supporting recent studies demonstrating the persistent risk 
of reactivation among foreign-born persons with latent tuberculosis infection (14, 18). In 
addition, there is an increased tuberculosis case rate in Mexico-born persons in the United 
States for more than 25 years; the reasons for this delayed increase in rate among Mexico-
born persons (but not among foreign-born other persons) are not clear, but this finding might 
be partly due to recent transmission via return visits to Mexico, exposure to cases with 
infectious tuberculosis visiting from outside the United States (e.g., friends or relatives), or a 
higher prevalence of medical conditions that increase the risk of progression from latent 
tuberculosis infection to tuberculosis disease.
During 2000–2010, the Mexico-born population experienced an overall 14.5% decline in 
tuberculosis case count. Stratified analysis by years since U.S. entry provides some insight 
into the driving forces behind the declining incidence of tuberculosis among Mexico-born 
persons. Specifically, the overall decline in tuberculosis morbidity among Mexico-born 
persons was not due to a change in tuberculosis case rate among newly arrived (<1 yr) 
persons, as this rate remained relatively constant during the study period. Rather, the change 
in trend may be attributed to changing demographics of the underlying population (i.e., 
fewer newly arrived persons), and lower tuberculosis rates among non–recently arrived (>5 
yr) Mexico-born persons. At the same time, the extent of the decline was dampened by a 
large increase in the size of the non–recently arrived Mexico-born population.
These findings have important implications regarding the close relationship between 
population shifts and tuberculosis morbidity among Mexico-born persons living in the 
United States. As immigration from Mexico has declined, the proportion of Mexico-born 
cases that are newly arrived (<1 yr) has become a smaller fraction of all Mexico-born 
tuberculosis cases diagnosed in the United States (only 11.4% in 2010). Given this trend, 
public health authorities must be mindful not to devote resources solely focused on the 
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newly arrived to the exclusion of Mexico-born persons that have been in the United States 
for longer periods of time, as this latter group has become the main driver of tuberculosis 
morbidity among the Mexico-born population. Moreover, these findings demonstrate how 
variable patterns of immigration among Mexico-born persons have impacted (and will likely 
continue to impact) tuberculosis morbidity, suggesting that years since U.S. entry may be an 
unreliable measure to guide tuberculosis prevention and control strategies.
The past several years have seen an emphasis on preimmigration screening as a mechanism 
to reduce the burden of tuberculosis among foreign-born persons living in the United States. 
Previous studies have demonstrated the effectiveness of this intervention for foreign-born 
persons from countries other than Mexico (18, 31, 32), and every case of tuberculosis 
diagnosed and treated overseas directly decreases tuberculosis morbidity in the United 
States. However, results of our analysis suggest that, among the Mexico-born population, 
preimmigration screening should not be the only strategy pursued.
First, the proportion of Mexico-born persons with tuberculosis who are diagnosed with 
tuberculosis within 1 year of arrival is decreasing every year, and this decline began before 
the new preimmigration screening instructions were implemented (22.7% in 2000 compared 
with 13.7% of all Mexico-born cases in 2007). Thus, strategies focusing on the newly 
arrived (<1 yr) are not sufficient to address the large contribution of reactivation tuberculosis 
to the total morbidity among Mexico-born persons.
Second, in contrast to other foreign-born populations, only a small proportion of Mexico-
born persons (<3%) pass through preimmigration screening (33); instead, many enter the 
United States as a visitor, temporary resident, or without a visa altogether (34). A recent 
study in California found that, among Mexico-born persons undergoing preimmigration 
screening, only two cases were diagnosed within 6 months after arrival from October 2006 
to September 2007 (before the new preimmigration screening instructions were 
implemented) (32). During the same time period, 52 cases were diagnosed within 6 months 
after arrival in California among Mexico-born persons without preimmigration screening 
(U.S. Centers for Disease Control and Prevention, National Tuberculosis Surveillance 
System, unpublished data). Thus, even if preimmigration screening were 100% sensitive, it 
would not address the large number of persons from Mexico who enter into the United 
States without screening.
Traditionally, targeted testing for latent tuberculosis infection has focused almost 
exclusively on persons who have newly (<1 yr) or recently (1–5 yr) arrived in the United 
States (12), due to elevated tuberculosis case rates among these populations (16, 35). Our 
findings support this approach—we found that the case rate among newly or recently arrived 
Mexico-born persons is more than twice that of nonrecent arrivers. A recent study concluded 
that elevated tuberculosis case rates among newly arrived persons might be primarily due to 
prevalent tuberculosis rather than a higher risk of reactivation (18). This finding further 
supports the focus of targeted testing on newly arrived Mexico-born persons, (most of whom 
have not passed through preimmigration screening), as targeted testing might also detect 
prevalent tuberculosis disease (36).
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In addition to the traditional focus on newly (<1 yr) and recently (1–5 yr) arrived Mexico-
born persons, our findings also support extending targeted testing and treatment to non–
recently arrived (>5 yr) Mexico-born persons. Others have suggested that targeted testing of 
foreign-born persons, regardless of time living in the United States, could aid progress 
toward tuberculosis elimination (10, 15, 17, 18). Tuberculosis genotyping studies have 
estimated that only 25% of Mexico-born cases in the United States are due to recent 
transmission, meaning that the vast majority are likely due to reactivation of latent 
tuberculosis infection (11, 37).
However, addressing the burden of latent tuberculosis infection among this population can 
be daunting; an estimated 2.3 million Mexico-born persons living in the United States are 
latently infected with tuberculosis (38). Strategies such as targeted testing for latent 
tuberculosis infection among subgroups of non–recently arrived Mexico-born persons with 
higher risk for progression to tuberculosis disease (e.g., diabetes mellitus) might be more 
feasible and cost effective (10, 12, 39, 40). In addition, new tools against latent tuberculosis 
infection, including more specific diagnostics (36, 41) and shorter courses of therapy (42), 
could help alleviate the workload of treatment for this population.
Overall, the unique epidemiology and demographics of the Mexico-born population dictate a 
tailored approach to tuberculosis prevention and control. Most jurisdictions will continue to 
justly prioritize their resources on newly (<1 yr) and recently (1–5 yr) arrived Mexico-born 
persons. However, although this approach targets the Mexico-born population with the 
highest tuberculosis case rate and is cost effective (10), it does not address the large and 
growing pool of latent tuberculosis infection among non–recently arrived Mexico-born 
persons, and therefore will not be sufficient to achieve substantial future reductions in 
tuberculosis in this population. As a result, future trends in tuberculosis morbidity among 
Mexico-born persons will likely continue to be driven by the non–recently arrived 
population.
This study had several limitations. First, the foreign-born other population is not 
homogenous, and while useful as a referent to compare with the Mexico-born population, 
we are limited in our ability to interpret trends among the foreign-born population from 
countries other than Mexico. Second, persons from other Latin American countries may be 
misclassified as Mexico-born in the U.S. National Tuberculosis Surveillance System, 
particularly if they passed through Mexico en route to entering the United States. Third, 
reports of years since U.S. entry rely on self-report and can be complicated by multiple 
entries for a given individual. Fourth, American Community Survey population data are 
estimates, and not census counts of the population at risk; however, the U.S. Census does 
not record country of birth.
We found the overall decline in tuberculosis morbidity among Mexico-born persons may be 
attributed to two factors: (1) fewer newly arrived (<1 yr) persons; and (2) lower tuberculosis 
case rates among non–recently arrived (>5 yr) persons. At the same time, the extent of the 
decline was dampened by an unchanged tuberculosis case rate among newly arrived persons 
from Mexico and a large increase in the non–recently arrived Mexico-born population. If 
current trends continue, tuberculosis morbidity among Mexico-born persons will continue to 
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be driven by the non–recently arrived population. To achieve substantial reductions in 
tuberculosis among Mexico-born persons living in the United States, more effective 
prevention and control measures (e.g., improved testing for and treatment of latent 
tuberculosis infection) are needed, particularly in those who have been living in the United 
States for more than 5 years.
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Annual tuberculosis case rate by origin, United States, 2000–2010. Solid line (red), annual 
tuberculosis case rate among foreign-born persons from countries other than Mexico 
(foreign-born other); dashed line (blue), annual tuberculosis case rate among Mexico-born 
persons; dotted line (black), annual tuberculosis case rate among U.S.-born persons.
Baker et al. Page 13














(A) Percent of tuberculosis cases born in Mexico, by state, United States, 2000–2010. 
Darkness of shading corresponds to the proportion of tuberculosis cases that occurred 
among Mexico-born persons. Dark blue–shaded states reported over 15% of tuberculosis 
cases among Mexico-born persons; medium blue–shaded states reported 5–15% of 
tuberculosis cases among Mexico-born persons; and light blue–shaded states reported less 
than 5% of tuberculosis cases among Mexico-born persons. States with cross-hatching 
reported insufficient numbers of cases among Mexico-born persons to report a proportion. 
(B) Tuberculosis case rates (per 100,000) among Mexico-born persons, by state, United 
States, 2000–2010. Darkness of shading corresponds to tuberculosis case rate among 
Mexico-born persons. Dark blue–shaded states had tuberculosis case rates of over 20 per 
100,000 among Mexico-born persons; medium blue–shaded states had tuberculosis case 
rates between 15 and 20 per 100,000 among Mexico-born persons; and light blue–shaded 
states had tuberculosis case rates under 15 per 100,000 among Mexico-born persons. States 
with cross-hatching reported insufficient numbers of cases among Mexico-born persons to 
report a tuberculosis case rate.
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Tuberculosis case rate among Mexico-born and foreign-born other persons, by years since 
entry into the United States, 2000–2010. Solid line (red), tuberculosis case rate among 
foreign-born persons from countries other than Mexico (foreign-born other); dashed line 
(blue), tuberculosis case rate among Mexico-born persons.
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Annual tuberculosis case rates among Mexico-born persons by years since entry into the 
United States, 2000–2010. Solid line (red), tuberculosis case rate among newly arrived 
Mexico-born persons (<1 yr since U.S. entry); dashed line (blue), tuberculosis case rate 
among recently arrived Mexico-born persons (1–5 yr since U.S. entry), dotted line (black), 
tuberculosis case rate among non–recently arrived Mexico-born persons (> 5 yr since U.S. 
entry). If the P value is 0.05 or less, then slope is considered significantly different than 
zero.
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Table 1
Select demographic and clinical characteristics of persons with tuberculosis by origin, United States, 2000–
2010 (n = 152,814)*
Characteristics Mexico-Born (n = 20,254) n (%)
Foreign-Born Other 
(n = 63,371) n (%) P Value
† U.S.-Born (n = 
69,189) n (%) P Value
‡
Any substance abuse
 Yes 3,455 (17.1) 3,345 (5.3)
<0.0001
17,916 (25.9)
<0.0001 No 16,006 (79.0) 58,211 (91.9) 48,389 (69.9)
 Unknown 793 (3.9) 1,815 (2.9) 2,884 (4.2)
Homelessness
 Yes 1,014 (5.0) 1,144 (1.8)
<0.0001
6,693 (9.7)
<0.0001 No 18,938 (93.5) 61,409 (96.9) 61,695 (89.2)
 Unknown 302 (1.5) 818 (1.3) 801 (1.2)
Correctional institution residence
 Yes 1,326 (6.6) 935 (1.5)
<0.0001
3,214 (4.7)
<0.0001 No 18,900 (93.3) 62,267 (98.3) 65,818 (95.1)
 Unknown 28 (0.1) 169 (0.3) 157 (0.2)
Disease site




 Extrapulmonary only 3,789 (18.7) 15,723 (24.8) 11,973 (17.3)
 Both 1,988 (9.8) 5,307 (8.4) 5,952 (8.6)
 Unknown 15 (0.1) 50 (0.1) 64 (0.1)
Chest radiograph results (n = 121,200)
§
 Cavitary 5,393 (32.8) 11,547 (24.3)
<0.0001
16,793 (29.4)
<0.0001 Noncavitary 10,757 (65.4) 35,289 (74.1) 39,064 (68.4)
 Unknown/not done 300 (1.8) 762 (1.6) 1,295 (2.3)
Sputum smear result (n = 121,200)
§
 Positive 8,894 (54.1) 20,438 (42.9)
<0.0001
25,719(45.0)
<0.0001 Negative 6,436 (39.1) 23,308 (49.0) 21,451 (37.5)
 Unknown/not done 1,120 (6.8) 3,852 (8.1) 9,982(17.5)
HIV status (n = 121,110)
∥
 Positive 835 (6.6) 3,185 (6.8)
<0.0001
7,001 (11.4)
<0.0001 Negative 9,201 (72.7) 30,932 (65.9) 36,237 (58.9)
 Unknown/not done 2,615 (20.7) 12,816 (27.3) 18,288 (29.7)
Previous tuberculosis
 Yes 800 (4.0) 3,359 (5.3)
<0.0001
3,296 (4.8)
<0.0001 No 19,270 (95.1) 59,398 (93.7) 65,345 (94.4)
 Unknown 184 (0.9) 614 (1.0) 548 (0.8)
Drug resistance
 Isoniazid-monoresistant





** 216 (1.1) 887 (1.4) 294 (0.4)
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Characteristics Mexico-Born (n = 20,254) n (%)
Foreign-Born Other 
(n = 63,371) n (%) P Value
† U.S.-Born (n = 
69,189) n (%) P Value
‡
 Other first line resistance 118 (0.6) 270 (0.4) 298 (0.4)
 Pyrazinamide-monoresistant
†† 823 (4.1) 466 (0.7) 552 (0.8)
 Susceptible 13,375 (66.0) 42,936 (67.7) 48,154 (69.6)
 Unknown/not done 4,675 (23.1) 14,097 (22.3) 17,780 (25.7)
Outcome (n = 118,381)
‡‡
 Completed therapy 13,969 (87.1) 45,862 (91.6)
<0.0001
48,954 (93.6)
<0.0001 Moved/lost to follow-up 1,593 (9.9) 2,926 (5.9) 1,707 (3.3)
 Other/unknown 473 (3.0) 1,256 (2.5) 1,647 (3.2)
Foreign-born other indicates foreign-born from countries other than Mexico.
*
Excluding 539 cases with no reported information on birth country or born as U.S. citizens outside of the United States.
†
For Chi-square comparison between Mexico-born and foreign-born other.
‡
For Chi-square comparison between Mexico-born and U.S.-born.
§
Among cases with pulmonary tuberculosis.
∥
Excluding cases reported in California.
¶
Isoniazid-monoresistant was defined as resistance to isoniazid, but susceptible to rifampin.
**
Multidrug-resistant was defined as resistance to at least isoniazid and rifampin.
††
Among cases with pyrazinamide-rnonoresistance and known genotyping results (2005–2010), 56.7% of isolates were Mycobacterium bovis 
(89.5% among Mexico-born, 12.2% among foreign-born other, and 51.8% among U.S.-born).
‡‡
Data not available for cases reported in 2009 or 2010; does not include patients who died.
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Table 2
Tuberculosis case counts and tuberculosis case rates by age group, origin, ethnicity, and proximity to the 
United States–Mexico border, 2005–2010
*
Nonborder States n (Rate) Border States
†
Nonborder Areas Border Areas
‡
n (Rate)
% Difference in 
Rate
§ n (Rate) % Difference in Rate
∥
Children (<15 yr)
 Foreign-born other 717 (9.4) 150 (7.1) −24.6 12 (6.9) −27.2
 Mexico-born 103 (5.5) 121 (5.0) −10.0 36 (8.9) +60.9
 U.S.-born Hispanic 812 (2.5) 656 (1.9) −25.3 256 (4.3) +72.9
 U.S.-born non-Hispanic 1,273 (0.5) 343 (0.8) +48.4 10 (0.3) −36.6
Adults (⩾15 yr)
 Foreign-born other 22,025 (19.0) 10,075 (23.6) +24.6 879 (33.7) +77.7
 Mexico-born 3,818 (16.8) 4,826 (13.2) −21.0 1,734 (28.2) +68.0
 U.S.-born Hispanic 1,342 (4.0) 1,668 (3.7) −7.4 654 (7.9) +95.9
 U.S.-born non-Hispanic 19,568(2.1) 4,944 (3.0) +41.9 313 (2.4) +17.7
Foreign-born other indicates foreign-born from countries other than Mexico.
*
Data for populations in border area public use microdata areas were not available before 2005.
†
States with a geopolitical border with Mexico (i.e., California, Texas, New Mexico, and Arizona).
‡
Public use rnicrodata areas directly bordering Mexico.
§
Percent difference in tuberculosis case rate in nonborder areas of border states compared to nonborder states.
∥
Percent difference in tuberculosis case rate in border areas of border states compared to nonborder states.
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